French healthcare company Sanofi announced on Tuesday positive Phase I/II study interim results for its first mRNA-based vaccine candidate.
Sanofi said initial data from these results showed neutralizing antibody seroconversion in 91%-100% of study participants, two weeks after a second injection, across all three dosages tested.
"These results will clearly help inform the path forward for our mRNA development programs," said Jean-Francois Toussaint, global head of research and development at Sanofi Pasteur.
&uuid=(email))